Top 10 Early Stage Investors in Biotechnology & Life Sciences
| Rank | Investor Name |
|---|---|
| 1 | ORBIMED Healthcare Fund Management |
| 2 | RA Capital Management |
| 3 | ARCH Venture Partners |
| 4 | Eli Lilly and Company |
| 5 | Even One Ventures |
| 6 | BVF Partners |
| 7 | Atlas Ventures |
| 8 | Frazier Healthcare Partners |
| 9 | Logos Capital |
| 10 | Novo Holdings |
Early stage activity in this category is led by institutional venture franchises and category specialists. Clinical data readouts and large pharma acquisition appetite set the pace of investment across biotech, with capital concentrating in firms that can underwrite science. For a company raising a priced early round, this list identifies the firms with the most active recent presence in the category.
The CapitalDart directory identifies the right person to contact at each of these firms, with their individual investment criteria.
Create a free account and get the contacts for the investors above.
Rankings cover January 2025 to July 2026 investment activity in US and Canada companies. Seed and early-stage rankings measure deal participation, not suitability for every raise.